[January 21, 2013]

Pathway Genomics Joins Blue Shield of California's Preferred Provider Network

Pathway Genomics Corporation, a San Diego-based clinical laboratory that offers genetic testing services internationally, can now provide genetic testing services to physicians participating in Blue Shield of California's Preferred Provider Network. With 3.3 million members, Blue Shield of California has an HMO network of more than 34,000 physicians and 290 hospitals, and a PPO network that includes more than 60,000 physicians and 351 hospitals.

"Through the network, Blue Shield of California members now have access to Pathway Genomics' genetic testing servces," said Jim Plante, Pathway Genomics' founder and CEO. "Currently, this includes testing for a person's genetic propensity for specific medication responses, inherited genetic conditions, and the risk of serious complex health conditions."

Pathway Genomics' laboratory is accredited by the College of American Pathologists (CAP) and accredited in accordance with the U.S. Health and Human Services' Clinical Laboratory Improvement Amendments (CLIA) of 1988. Pathway Genomics is also a member of the American Clinical Laboratory Association (ACLA). The company consists of more than 40 scientific and medical professionals, including medical doctors, molecular geneticists, a genetic counseling service, and an expert scientific advisory board.

About Pathway Genomics

Pathway Genomics owns and operates a genetic testing laboratory in San Diego, California, that is accredited by the College of American Pathologists (CAP), accredited in accordance with the U.S. Health and Human Services' Clinical Laboratory Improvement Amendments (CLIA) of 1988, and licensed by the state of California. Using only a saliva sample, the company incorporates customized and scientifically validated technologies to generate personalized reports, which address a variety of medical issues, including an individual's carrier status for recessive genetic conditions, food metabolism and exercise response, prescription drug response, and propensity to develop certain diseases such as heart disease, type 2 diabetes and cancer. For more information about Pathway Genomics, visit www.pathway.com.

[ Back To Technology News's Homepage ]